Amino Acid Supplementation in Continuous Renal Replacement Therapy
NCT ID: NCT06835816
Last Updated: 2025-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2025-02-03
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Blood samples are drawn and then dialysis start without amino acid supplementation. After a few hours samples are drawn from blood and dialysate. Then patients are given amino acid supplementation (33.5g/24hrs) for 20-24 hours. New samples are drawn and amino acid supplementation is increased to 67g/24hrs and new samples are drawn after additional 24 hours. Then CRRT will continue with the full amino acid supplementation (standars of care).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Amino Acid Loss During Continuous Renal Replacement Therapy
NCT06659835
Iatrogenic Deficiencies in ICU Patients With Prolonged Continuous Renal Replacement Therapy
NCT06983197
Timing of Renal Replacement Therapy in the Critically Ill Patients
NCT03629977
Renal Physiology During Continuous Renal Replacement Therapy
NCT04114747
Effect of CRRT Duration on Solute Removal
NCT04458571
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All patients
All patients will start CRRT treatment without amino acid supplementation After a few hours samples are drawn from blood and dialysate Patients then receive low dose of supplementation for 24 hours (33.5g, 250 ml Glavamin, Fresenius Kabi) and new samples are drawn After that patients receive full supplementation (67g, 500 ml Glavamin, Fresenius Kabi) for the rest the of CRRT treatment. After 24 hours of this treatment new samples are drawn.
Amino acid supplementation (Glavamin, Fresenius Kabi)
Mixture of amino acids (67 g / 500 ml) given intravenously
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Amino acid supplementation (Glavamin, Fresenius Kabi)
Mixture of amino acids (67 g / 500 ml) given intravenously
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Muscle disease
* Neurodegenerative disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Karolinska University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonathan Grip
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan Grip, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Karolinska University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Karolinska University Hospital
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-07570-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.